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REVIEW
Abstract: Risk assessment constitutes an essential component of genetic counseling and
testing, and the genetic risk should be estimated as accurately as possible for individual and
family decision making. All relevant information retrieved from population studies and pedigree
and genetic testing enhances the accuracy of the assessment of an individual’s genetic risk.
This review will focus on the following general aspects implicated in risk assessment: the
increasing genetic information regarding disease; complex traits versus Mendelian disorders;
and the influence of the environment and disease susceptibility. The influence of these factors
on risk assessment will be discussed.
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Introduction
The beginning of the 21st century has seen unprecedented advances in genome
understanding. Since completing the sequence of the human genome there has been
an explosion of available genetic information, providing unparalleled opportunities
in understanding disease, drug design and toxicology, ecology, and risk assessment.
Risk assessment is an essential part of genetic testing and counseling, and should be
calculated as accurately as possible to enable both the clinician and the patient (or
his/her family) to make decisions. An individual’s genetic risk refers to the probability
of the individual carrying a specific disease-associated mutation, or of being affected
with a specific genetic disorder. The calculation of genetic risk should incorporate
all available information at a particular point in time, such as the results of genetic
testing (mutations, polymorphic markers); the presence of an independent risk factor
derived from genetic test results; genetic test results on either or both parents, siblings,
and close relatives (the probability of carrying a particular mutation or mutations
often differs considerably among families and even among individuals within the
same family); the ethnic background of each parent; an overall mutation rate for
each ethnicity; and, if possible, the frequency of mutation in the population. Risk
assessment should be looked at as an ongoing process of analysis of estimates.
Genetic risk data obtained from population studies are commonly used as a starting
point in genetic risk assessment (prior probability of the individual having the disease).
These estimates are mostly based on published data from a finite number of cases in
specific and highly monitored populations (Ioannidis et al 2002). A good example of
genetic risk variation between ethnic groups has been described for cystic fibrosis.
Cystic fibrosis is caused by mutations in the cystic fibrosis transmembrane
conductance regulator gene (CFTR) (OMIM nrs 602421; 219700(CF)). The disease-
allele distribution of the CFTR gene varies greatly among different ethnic groups,
leading to different inputs when calculating risk of disease. In CFTR, for example, if
the individual in question is Caucasian European there are plenty of genomic data,
making it easier to calculate the prior probability. Conversely, if little information is
available for the population subgroup, several approximations might be done to obtain
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a prior probability (see Bobadilla et al 2002). When looking
at the genetic risk for a determined population, attention
should be brought to the possible misrepresentation of
experimental data such as the allelic bias introduced by
migrating populations, the study settings that established
the genetic association (moment of diagnosis of a certain
condition in a population and time of the genetic study),
environmental factors, misclassification of outcome
(conditions grouped under the same outcome but clearly
distinct; for example see Gambaro et al 2000), and others.
Nevertheless, researchers have calculated that only in
extreme situations (few ethnic groups, great differences in
disease and genotype frequencies) will any substantial
misinterpretation occur (Wacholder et al 2000).
Another aspect reflects the development of the human-
genome map and the advances in molecular technology,
together with large-scale population-based studies, requiring
close integration of genetic and epidemiologic research
(Gambaro et al 2000). The post-genome era has been
responsible for a flood of new data with studies reporting
an association between genetic variation and disease-related
outcomes (Halldorsson et al 2004; Hu et al 2004). With
several million single-nucleotide polymorphisms (SNPs)
characterized in the human genome, the number of possible
genetic associations that can be tested is limited only by the
rate at which laboratories can type these polymorphisms.
The application of common genetic variations in association
with studies to generate potential risk profiling using data
from multiple vulnerability genes may play a key role in
the early identification of high-risk individuals and groups
of patients (The International SNP Map Working Group
2001). Recent studies have shown unprecedented sequence
and haplotypic diversity in the genome (Durrant et al 2004;
Smith et al 2004; Zhang et al 2004). If more than a
polymorphism in a gene shows association with disease it
must be established which variant(s) cause(s) predisposition.
This is easy to demonstrate in animal models, where the
whole genome can be experimentally manipulated to
identify all variant(s). In humans, evaluating the association
of different but closely related haplotypes may lead to the
identification of the ancestral segment(s) that carry the
predisposing/protective alleles (for example, see Funke et
al 2004; Kokubo et al 2004). It should be noted that different
studies on the same genetic association sometimes have
discrepant results, each of them needing to be carefully
monitored and tailored to the casual assessment (Ioannidis
et al 2003).
For any given genotype-disease association, considerable
effort is needed to assemble all available studies. As data
accumulate, maintaining up-to-date reviews and information
of each genotype-outcome association is becoming almost
impossible. A more feasible approach may be to establish
an automated system, such as a web-based database in which
submitted data are classified by polymorphism, and outcome
could be constructed. This database would need to be
continuously updated, submission of both negative and
positive findings in a standard format would be encouraged,
and users would be able to assess a systematically up-to-
date summary estimate of the effect associated with a certain
allele or genotype. For this database to work, some sort of
reward for researchers who contribute would need to be
created. Also, some sort of critical analysis would need to
be performed to revise the data entries.
Including the results from genetic testing can
dramatically increase the accuracy of genetic risk
assessment. Recent advances in genetic information and
technology have led to an explosion in molecular testing
for mutations and genome diversity. However, analytical or
interpretative laboratory errors may affect risk assessment
directly (false detection of mutation or polymorphism) or
indirectly by altering estimates of allele distribution, carrier
frequencies, and so on. The available technical platforms
for use in genetic testing such as PCR, RFLPs, DHPLC,
cDNA microarrays, DNA-chips, automated sequencing
(which has become increasingly low-cost technology), RNA
technology (RNA interference, antisense RNA),
nanotechnology-based labeling, among many others, have
contributed to a great expansion in the number of DNA tests
capable of being used in the clinical environment (see also
Amos and Grody 2004; Trent et al 2004). It should be
emphasized that when several genes and/or environmental
factors are involved in the genesis of a given disorder, the
genetic testing for correct risk assessment is far from
straightforward.
Genetic risk assessment in the
clinical environment
Genetic counseling, developed to address the medical and
social consequences of Mendelian disorders, has become
an integral part of genetic testing. Genetic counseling as
currently practiced is focused on the assessment of genetic
risk, education of at-risk individuals and family members
about the disease management and manifestation, education
about reproductive options, and provision of psychologicalTherapeutics and Clinical Risk Management 2005:1(1) 17
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and emotional support to cope with mostly untreatable
diseases. Analysis based on Baye’s theorem is routinely
applied to calculate genetic risk in complex pedigrees and
to estimate the probability of having or lacking a disease-
causing mutation after a negative test result is achieved
(Claus 2000). In brief, Baye’s theorem states that the
probability of a disease or condition after having performed
a test is dependent on two things: the specificity and
sensitivity of the test used (test characteristics), and the
probability of that disease or condition before conducting
the test (or prior probability). Whilst the first is rather
straightforward as it depends solely on the technology
(whether the mutation/alteration in question is susceptible
to being detected and characterized with the technological
platform in hand; possible bias introduced by a test being
more sensitive in detecting one mutation than another), the
latter is far more complex as many factors can influence the
calculation and assessment of the prior-probability (see
above).
Also, the genetic background of a specific disease greatly
influences the assessment of risk for that particular disease,
whether a single gene disorder or a more complex disease.
A clarification of general issues involved in genetic risk
assessment for both types of disease will be attempted. A
substantial number of common human diseases are
determined wholly or in part by genetic factors, usually
characterized by the recognition of specific heritable
conditions and identification of familial risk factors.
Generally, genetic risk assessment has been largely focused
on the evaluation of risk in Mendelian disorders, where a
disease causing mutation in a single gene has high
penetrance, producing an observable, often profound effect
on phenotype. However, most common disorders are
complex and multifactorial, and are presumed to result from
the additive effect of mutations of low penetrance at multiple
loci. This way, when considering Mendelian disorders, the
assessment of risk is mainly relevant for the individual’s
own decision making through enhanced impartial
information. In mainly complex disorders, however, the
estimation of risk assesses the susceptibility of the individual
to a certain disease and is essentially used towards risk
modification through medical/behavioral intervention. In
this case, the primary role of genetic risk assessment is to
promote medical interventions (eg, through presymptomatic
medication) or behavioral changes (eg, lifestyle and diet)
in healthy individuals, which could contribute to a risk
modification. Of utmost importance is the actual perception
of risk by the individual. Presumably, a more realistic
perceived risk (after a correct risk assessment is performed)
will motivate the initiation and maintenance of health-
protective behaviors at a level that is appropriate for the
individual’s level of risk. The time of risk perception depends
heavily on psychological and cognitive variables and
influences adherence to putative therapeutics (Weitzel et al
2003).
Mendelian disorders
In Mendelian disorders, the affected individuals are
perceived due to obvious symptoms or signs, or family
history. In these single-gene disorders, risk assessment is
primarily based on: (1) the results derived from genetic
testing in direct diagnosis of symptomatic individuals (eg,
Huntington’s disease) or confirmation of diagnosis of a
heritable disorder; (2) the assessment of the relatives’ genetic
risk, as relatives have an a priori higher risk that can be
quantified; (3) prenatal diagnosis, where the risk for
offspring can be easily calculated; and (4) the predictive
evaluation, considering that an at-risk individual harboring
the disease-causing mutation/allele, given enough time, will
develop symptoms. The following example could help
illustrate what has been stated: the carrier of a mutation has
a 50% probability of passing the mutation to an offspring,
and a 50% probability of having received the mutation from
one parent. Based on this, the probability of being a carrier
by the relatedness of the individual to an affected family
member or obligate carrier can be estimated. For autosomal
recessive diseases, provided that the carrier frequency in
the general population is sufficiently small, the carrier’s risk
decreases by half at each “step” across a pedigree from the
affected family member to a given individual. Some
exceptions exist, as for X-linked recessive diseases, where
the carrier’s risk decreases by half at each “step” from one
female member to another female member in the preceding
or successive generation of the pedigree.
It should be noted that in recessive diseases there is a
strong possibility that a disease-associated mutation is
missed. In contrast, dominant disorders are usually caused
by more specific mutations, which are usually easier to
identify and follow across a pedigree. In recessive disorders,
it is of paramount importance to consider the effect of
consanguinity: alleles that are identical because they derive
from a single allele present in a common ancestor are defined
as being identical by descent. Alleles that are the same but
that derive from two different and apparently unrelatedTherapeutics and Clinical Risk Management 2005:1(1) 18
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sources are defined as being identical by state.
Consanguineous mating increases the frequency of
autozygosity for two mutant alleles that are identical by
descent.
Common complex disease
susceptibilities
The genetic architecture of complex disease is not fully
understood (Risch 2000). Most common complex disorders
are assumed to result from the additive effect of
alterations/mutations of low penetrance at multiple loci
(Glazier et al 2002). Normally, when these mutations occur
individually they may have no defective phenotypic effect.
Then again, these mutations may act in cooperation with
each other, usually in the presence of environmental stimuli,
leading directly to disease or to an increase in disease risk.
Accordingly, these mutations can be regarded as
predisposing mutations, as they are necessary to cause
disease but alone they are not sufficient. It is possible, that
the risk for some common diseases is due to a very large
number of loci, with each having a low frequency of disease-
predisposing alleles (Pritchard 2001; Wang et al 2003). For
example, a disease with 10% incidence in the population
might reflect 100 independent monogenic diseases, each
with high penetrance. This would, however, imply a higher
relative risk to family members than actually observed for
complex diseases. Actually, the perceived drop in relative
risk for family members suggests (but does not prove) that
the biggest fraction of the risk could be credited to a small
number of loci with a higher frequency of alleles
predisposing to disease, as seen for example for Factor V
Leiden in deep venous thrombosis (Alhenc-Gelas et al 2001;
Castoldi and Rosing 2004) and ApoE ε4 allele in
Alzheimer’s disease (Wang et al 2000; Lambert et al 2002).
Non-Mendelian genetics also contribute to genetic risk
through a number of different mechanisms, including de
novo mutations and mosaicism. A de novo mutation is a
mutation that is absent from the somatic cells of the parents,
but present in the somatic cells of the offspring. A de novo
mutation may cause a subset of germ cells to have the
mutation; ie, isolated germline mosaicism. Germline
mosaicism may or may not be noticeable as a de novo
mutation in offspring. Non-Mendelian genetics also
influence genetic risk assessment through a number of other
mechanisms, including genomic instability (anticipation),
non-paternity, imprinting (epigenetics), positional effects
of genes (which can sometimes be viewed as a multifactorial
mechanism), and mitochondrial inheritance (for further
reading see Bridge 1997; Young 1999).
One could be led to assume that there is a clear distinction
between these two models: one, with the predominance of
genetic influence – Mendelian; and the other, with the
predominant influence of the environment. The distinction
between the two models is far from clear-cut. In reality,
they refer to the extremes of the wide spectrum of
disease/disorder where genetics plays a significant role, with
most disorders usually situated somewhere in the middle of
the spectrum. It is increasingly recognized that the so called
Mendelian disorders are complex diseases where the
environment plays a central role in disease causation. This
one disease can be decomposed in several simpler disorders
for which a risk can be calculated. Variability in some
heritable disorders is clearly mediated by the environment,
eg, dietary phenylalanine in classic phenylketonuria (PKU).
Even in the absence of identifiable environmental influences,
genotype often does not completely predict phenotype, eg,
Huntington’s disease. The presence and/or number of
pathogenic CAG repeats does not predict the age of onset
or the severity of phenotype. The presence of a major
disease-causing allele should be considered more
“predisposing” than predictive. Thus far, most efforts that
have successfully identified genes associated with common
diseases have focused on population groups showing high
inheritance. Genes inherited in a Mendelian manner have
been identified as a cause of familial breast cancer, eg,
Alzheimer’s disease, Parkinson’s disease, and diabetes.
These genes are of great importance for the 5%–10% of
cases of high hereditability within families with common
complex diseases where a Mendelian disorder is identified.
It becomes less clear to determine what is solely genetic
and to distinguish inherited disease from acquired disease.
To calculate the genetic risk in these complex disorders,
one has to take into account all the inputs of risk; ie,
ultimately the risk associated with each factor involved in
the disease (number of genes causing or involved in the
disease and their associated risk, number of environmental
factors, etc). Whether all these factors have the same risk
input or some are more important to the outcome than others
needs to be clearly elucidated. The more factors involved
the more complex the models involved to accurately
calculate the probability of the individual developing the
disease, and for most diseases the factors (genetic,
environmental, and others) influencing the outcome are yet
to be fully characterized.Therapeutics and Clinical Risk Management 2005:1(1) 19
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In some cases, some simplifications of risk inputs can
be made. For example, when the risks conveyed by a single
gene are high, the testing for disease susceptibility may rely
on the Mendelian model described earlier; eg, the presence
of a BRCA1 mutation can confer a lifetime risk for breast
cancer of over 70% (Dunning et al 1999; Evans et al 2001).
The major advances in the understanding of the molecular
basis of cancer have made it possible to establish clear
parameters for genetic risk assessment in cancer patients,
especially for those individuals belonging to families in
which cancer has a strong inheritance link (Petrucelli et al
2002; Comings et al 2003). In these situations, the likelihood
that breast cancer risk is due to specific genetic susceptibility
(such as BRCA1 or BRCA2 mutations) can be easily
determined, and specific management strategies are now
defined for BRCA1 and BRCA2 mutation carriers (Wenham
et al 2003). Risk may be assessed as the likelihood of
developing breast cancer or as the likelihood of detecting a
BRCA1 or BRCA2 mutation. Clinical examples have told
us that optimal counseling may require the use of both
models, together with clinical judgment, to provide accurate
and useful information.
Genetic testing for Mendelian disorders is a complex
team approach with inputs from genetic counselors,
clinicians, nurses, and genetic researchers. Nevertheless,
genetic testing for common complex disease susceptibilities
is almost completely absent from medical practice. In
Mendelian disorders, the primary role of genetic testing is
to give some information that might allow healthcare
providers to assign relative risks to otherwise healthy looking
individuals, in an attempt to reduce the actual risk of
developing the disease (eg, health screening, pre-
symptomatic medication aimed at reducing or eliminating
one or more risk factors), or through behavioral changes
(eg, smoking, diet, and lifestyle). This risk reduction, or
more accurately described, risk modification, needs to be a
continuous effort aimed at achieving small changes in one
of the many small background risk factors involved. In these
cases, non- or presymptomatic individuals will most likely
be identified through public health or broad-spectrum
screening measures,  based on ethnicity or any factor
identified in population-based epidemiological studies.
Concluding remarks
The technologies for genetic testing continue to change, and
genetic risk assessment will no doubt become increasingly
integrated into all aspects of medical care. Advances in gene
identification and characterization, polymorphism
association studies, disease classification, and so on,
continue to rapidly provide new and clinically relevant
information that can contribute to a better detection,
evaluation, prevention, and follow-up strategies in human
disease. Additionally, prospective clinical trials need to be
conducted to define the optimal use of existing management
strategies, develop risk assessment instruments that
incorporate additional risk-factor information, and evaluate
populations for whom validated risk assessment approaches
do not yet exist.
It is becoming increasingly frequent that “healthy”
people seek predispositional genetic testing, and clinicians
should incorporate genetic risk assessment and management
into their routine screening and health maintenance
appointments. Attention should be brought to the current
limitations, uncertainties, legal, and psychological
implications of genetic risk assessment, eg, the right to not
know. As mentioned earlier, incorporating genetic data from
a close relative may be extremely useful for assessing the
genetic risk of an individual. But the relative may not wish
to know whether he/she is at risk and will not be tested for
the disease.
The powerful new methods and expansive scope
combine to project us into ethically unfamiliar territory. It
has been observed that discrimination or fear of
discrimination for medical, life, and disability insurance,
as well as employment discrimination, could undermine the
acceptance of genetic testing by individuals who otherwise
would choose to receive such information. These features
lend special urgency to questions of genetic ownership and
privacy, disease and normalcy, identity and genetic
determinism, and early diagnosis and therapy.
Abbreviations
ApoE4, apolipoprotein ε4 allele; BRCA1, breast cancer 1 gene; BRCA2,
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